No Effect on Liver Markers from CPAP Type for Sleep Apnea Patients
Patients suffering from non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) may turn to different ways to mark liver fat quantities, MD Magazine reports.
A team, led by David Hui, BBS, Medicine & Therapeutics, Chinese University of Hong Kong, examined whether intrahepatic triglyceride content measured by proton-magnetic resonance spectroscopy (MRS) could be the new gold standard for liver fat quantification.
While obstructive sleep apnea is linked to the development of NAFLD, proton-magnetic resonance spectroscopy estimating proton density fat fraction is a novel biomarker that is more sensitive than liver biopsies to determine steatosis grade in assessing changes in the liver fat content.
Get the full story at mdmag.com.
from Sleep Review https://ift.tt/2ATuz6I
Post a Comment